Guttify, a fast-growing diagnosis-first gut health company, is planning to raise ₹20 crore in its next funding round to accelerate its ambition of building one of India’s leading consumer gut health platforms. The company’s most recent funding valued Guttify at approximately ₹54 crore.
The proposed fundraise comes at a time when gut health is rapidly moving from a niche wellness conversation to a mainstream consumer health category, driven by rising awareness around digestion, metabolic health, the microbiome and preventive wellness.
Guttify is currently witnessing strong momentum, reporting 67% quarter-on-quarter growth, approximately 20% monthly growth in its user base, and a 40% repeat-user rate.
At the heart of Guttify’s strategy is its “Diagnosis-First” model, enabling consumers to understand their gut health before moving towards personalised guidance and targeted wellness solutions. Guttify’s affordable ₹399 DIY Gut Scan Kit has reached 30,000+ consumers, with its products averaging 4.5-star ratings. The kit serves as an entry point to personalised recommendations, expert guidance, and targeted gut-wellness solutions.
Unlike conventional wellness brands that begin with a product, Guttify is building a full-stack consumer journey around:
Diagnose → Understand → Personalise → Manage → Maintain
Guttify is building an integrated gut-health ecosystem combining at-home diagnostics, personalised recommendations, expert guidance, and clinically formulated solutions to help consumers better understand and manage digestive health.
“Gut health is becoming one of the most important consumer health conversations globally, but the category in India is still at an early stage,” said Mukul Shah, Co-founder of Guttify.
“We believe the next generation of gut health companies will go beyond simply selling probiotics or supplements. The opportunity is to build an ecosystem that helps consumers understand their gut better, personalise what they do next and then support them throughout their wellness journey. Our 67% quarter-on-quarter growth and increasing repeat behaviour give us confidence that Indian consumers are ready for this shift.”
₹20 crore raise to accelerate the next phase
Guttify is now preparing to raise approximately ₹20 crore to accelerate product innovation, strengthen its technology and diagnostic capabilities, invest in consumer education and expand distribution across Tier 1 and Tier 2 India.
The company also plans to significantly expand its portfolio across high-frequency digestive and metabolic wellness needs, including constipation, bloating, digestion, liver health and everyday gut wellness. The upcoming raise follows an approximate ₹4 crore follow-on funding round in February 2026 and an approximately $360,000 extended seed round in May 2025.
Guttify has raised more than ₹10 crore cumulatively to date, with participation from the family office associated with Unichem Laboratories, existing investors and prominent Indian and international HNIs, including Amandeep Singh Sodhi, co-founder of HOAGS Technologies.
As digestive and metabolic wellness gain mainstream attention, Guttify is building an India-first health platform focused on gut health, diagnostics, personalisation, and preventive wellness. The company aims to move beyond episodic solutions towards a daily, personalised approach to digestive health.
“Our objective isn’t to become another supplement company,” Shah added. “We want Guttify to become the platform consumers turn to when they want to understand, improve and maintain their gut health.”
With its next phase of growth, Guttify intends to deepen this diagnosis-led ecosystem while making science-backed gut wellness more accessible across India.